Rilpivirine (RPV) — Competitive Intelligence Brief

Rilpivirine (RPV) (Rilpivirine (RPV)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-nucleoside reverse transcriptase inhibitor (NNRTI). Area: Infectious Diseases.

phase 3 Non-nucleoside reverse transcriptase inhibitor (NNRTI) Reverse transcriptase Infectious Diseases Small molecule

Target snapshot

Rilpivirine (RPV) (Rilpivirine (RPV)) — Janssen Infectious Diseases BVBA. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the replication of HIV-1 by binding to the reverse transcriptase enzyme.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rilpivirine (RPV) TARGET	Rilpivirine (RPV)	Janssen Infectious Diseases BVBA	phase 3	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	Reverse transcriptase
tenofovir + emtricitabine + atazanavir-ritonavir	tenofovir + emtricitabine + atazanavir-ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + PI/r)	HIV reverse transcriptase, HIV protease
lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine	University of British Columbia	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
LPV/r + TDF/FTC or TDF/3TC	LPV/r + TDF/FTC or TDF/3TC	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
HIV therapy	HIV therapy	ViiV Healthcare	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple targets depending on specific agent (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5 co-receptor, gp120/gp41 envelope proteins)
Hepsera and lamivudine	Hepsera and lamivudine	University of Washington	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase
Switch to Triumeq	Switch to Triumeq	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Antiretroviral combination therapy (NRTI + INSTI)	HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-nucleoside reverse transcriptase inhibitor (NNRTI) class)

1. ViiV Healthcare · 4 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 3 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
5. Germans Trias i Pujol Hospital · 1 drug in this class
6. International Partnership for Microbicides, Inc. · 1 drug in this class
7. Janssen Infectious Diseases BVBA · 1 drug in this class
8. Janssen-Cilag S.p.A. · 1 drug in this class
9. Johns Hopkins Bloomberg School of Public Health · 1 drug in this class
10. Tibotec Pharmaceuticals, Ireland · 1 drug in this class